This month’s people on the move includes a new therapeutic lead at Advanced Clinical, with plans to create a network of investigation sites, as well as CEOs at AIT Bioscience and Pharm-Olam, who discuss plans for moving forward.
Escient Pharmaceuticals has entered the market after closing a $40m Series A financing round – and has contacted Eurofins Discovery for integrated drug discovery services.
The online marketplace for outsourced research has expanded its compliance solution to include animal welfare – and is working with customers to increase transparency and educate researchers.
Pepticom’s technology aims to ‘vastly reduce’ risk of failure in peptide drug candidates’ discovery and development, by utilizing artificial intelligence models.
GE Healthcare opens lab space to provide developers with access to protein and cell analysis technologies to encourage networking and partnering on R&D services.
The research models and services provider has acquired a company that specializes in tissue collections, and hematology, and immunology cell isolations to help meet its ‘ever-increasing’ client needs.
Organ-on-a-chip systems are poised to revolutionize drug development in many ways, say researchers advancing the technology, which could support gender-specific medicine, among other use cases.
Charles River Laboratories recently announced that Alzheimer’s Research UK selected the company to join the Dementia Consortium to help researchers progress projects to in vivo proof of concept.
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
GSK taps Lyell’s technology to delay ‘exhaustion’ of T cells and will explore creating a new platform to develop cell and gene therapies for rare cancers.
Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
A partnership between Sciex and Protein Metrics aims to make their services compatible with other software services available, enabling drug developers to work in an ‘open ecosystem.’
